Dr Hani Al-Salami (photo: CMBEBIH) and Professor Marco Falasca.

Two Curtin Health Innovation Research Institute (CHIRI) researchers have packed their research and taken it to the world stage at conferences in Bosnia and Herzegovina and London this month.

Dr Hani Al-Salami has recently returned from giving a headliner presentation at the CMBEBIH 2019 International Conference on Medical and Biological Engineering in Banja Luka, Bosnia and Herzegovina.

Meanwhile, Professor Marco Falasca is preparing to present at the 4th International Symposium on Immunotherapy at the Royal Society in London on 24-25 May.

Given a full hour to speak, Hani took the opportunity to talk about CHIRI and share his future perspective on his research area of expertise: bio-nanotechnological advancement in drug delivery and pancreatic tissue engineering.

Hani’s team at CHIRI is committed to identifying new pharmaceutical therapies for diabetes and age-related diseases using novel bio-nanotechnologies and pharmaceutical formulation targeted-delivery systems.

“At the heart of Europe, it was a great opportunity to showcase CHIRI and the cutting-edge research we do, as well as the strength of our bio-nanotechnology research and some of my lab’s key projects and achievements,” Hani said.

“I was also recently made an Honorary Professor at the University of Banja Luka, I took the opportunity to meet with university delegates about a collaborative research project we have underway between CHIRI and the university’s medical school.”

In London, Marco will speak on his 30 years of research into the deregulation of lipid metabolism in cancer biology, including his current CHIRI research focused on identifying therapy-based diagnostic strategies for pancreatic cancer and the use of cannabinoids for the enhancement of anticancer activity.

Organised by The Institute for Cancer Vaccines and Immunotherapy, the symposium brings together leading cancer immunologists, researchers and clinicians with interests in cancer immunotherapy; synergistic interactions of chemotherapy and the immune response; and the translation of knowledge in this area. Find out more at www.icvis.org.uk.